Case Study
Designing a Digital Clinical Architecture for Modern Researchers
Business Challenges Founded in late 2018 through a partnership with Pfizer and Bain Capital, Cerevel Therapeutics is a clinical-stage biopharmaceutical company working to transform the lives of people suffering from neuroscience diseases. As a new company with multiple clinicalstage products in development, Cerevel had the opportunity to create a new IT infrastructure without worrying about legacy systems, outdated equipment or long-term contracts with vendors. Cerevel is committed to being fast, lean and nimble, while also focused on a digital transformation driven by data and analytics.
■ Focused on developing therapies to treat disorders of the central nervous system ■ Founded in 2018 ■ Headquartered in Cambridge, MA
“ Development driven by data, a data-driven premier neuroscience company — that’s a call-to-action for me. I want to make sure that we have the back-end systems to actually live up to those statements.” Richard Gleeson Head of Clinical and R&D Technology, Cerevel
With over 10 drugs in development — including therapies to treat schizophrenia, epilepsy, and Parkinson’s in late clinical trials, Cerevel was looking for innovative strategies to manage numerous data streams coming in from multiple trials. Cerevel required a technology platform that could support the volume, variety and velocity of modern clinical trials utilizing multiple CROs and system providers. They required a system that could map and standardize the data plus enable near real-time analysis to make better business decisions faster. A decade ago Cerevel might have considered building their own server-based system, but instead they decided to take a buy, not build, approach. This ultimately saved time and money, while also giving the flexibility to scale up or down depending on the organization’s needs.
Success highlights 1. One clinical data cloud to serve as a single source of truth 2. Rapid access to data and realtime analytics for data driven decision-making 3. Fast and flexible study startups through out-of-thebox interoperability with other clinical systems